The Biggest Problem Facing Cannabinoid Therapies & the Company That is Doubling Down on Solutions


Ryan Allway

October 2nd, 2017

Exclusive, News, Top News


Medical cannabis has the potential to address everything from childhood epilepsy to the opioid epidemic, but there’s a big problem that researchers are facing when developing therapeutics – there’s no robust delivery mechanism available.

In a 2009 study, researchers found that bioavailability was wildly unpredictable for inhaled cannabis smoke (2% to 56%) and orally-consumed cannabinoids (4% to 20%). Many patients aren’t interested in smoking cannabis, but orally-consumed cannabis is subject to first-pass metabolism in the liver that mitigates its benefits. Topical delivery has become an alternative, but these formulations suffer from poor absorption and greasiness and oiliness.

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) has staked its business on transdermal and oral encapsulation cannabinoid delivery, which eliminates the negative side-effects of inhaled cannabis and avoids first-pass metabolism in the liver. After acquiring the worldwide rights to BiPhasix™, the company doubled down on another drug pharmaceutical delivery technology by locking up the worldwide rights to Solmic Solubilisation – a proprietary oral delivery technology.

What Makes It Different?

Pivot Pharma’s BiPhasix™ technology has been tested in FDA and EMA approved human clinical trials and been used to deliver an antiviral drug to treat infections in women.  In regulated studies, BiPhasix™ has been shown to improve drug permeation through the skin. Ongoing research shows that Biphasix™ is a non-invasive drug delivery system suitable for intra- and transdermal delivery of cannabinoids.

Acquisition of the worldwide rights to the Solmic Solubilisation Technology represents an expansion of Pivot’s cannabinoid delivery strategy. By packing active pharmaceutical ingredients in micelles, the innovative technology enables active ingredients to become water soluble without changing their composition and nature. These micelles mask unpleasant smells and tastes and increase the uptake of fat soluble ingredients into the gut and blood stream.

“Solmic’s water soluble technology has already been demonstrated in the nutraceutical and cosmeceutical markets in Europe,” said Pivot Pharma CEO Patrick Frankham. “The addition to Solmic, our second disruptive drug delivery technology platform for cannabinoids, strengthens our business strategy to be a market leader in the development and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC) based products.”

The combination of oral and transdermal delivery enables the company to develop therapeutics targeting a wide range of conditions.

Impressive Clinical Pipeline

Pivot Pharma is leveraging its cannabinoid delivery technology platforms to develop a robust pipeline of clinical products. The BiPhasix™ platform is targeting topical creams, while the Solmic platform targets orally consumed products.

PGS-N005 is a CBD topical cream developed with BiPhasix™ for the treatment of female sexual dysfunction. Despite up to 63% of sexually active women in the U.S. affected by FSD, the condition hasn’t garnered the same level of attention as male erectile dysfunction. Analysts believe that the FSD market could be worth more than $4 billion per year with a patient population of more than 50 million individuals.

PGS-N007 is a CBD topical cream developed with BiPhasix™ for the treatment of psoriasis. According to the National Psoriasis Foundation, the condition affects 7.5 million people in the United States  with a global prevalence range of 0.09% to 11.4%. Analysts believe that the market could be grow from $6.6 billion in 2014 to over $13.3 billion by 2024, which represents a 7.3% compound annual growth rate.

Using the Solmic technology platform, PGS-N001 will become the company’s first oral product incorporating cannabinoids to help cancer patients suffering from chemotherapy-induced vomiting, nausea, neutropenia, and anemia. The product will be registered as a Natural Health Product to shorten the development cycle and generate revenue more quickly than traditional pharmaceuticals with an estimated $30 billion market by 2021.

The Bottom Line

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) has acquired two cannabinoid delivery technologies that have powered a robust and growing product pipeline. Investors interested in companies solving cannabinoid delivery may want to take a closer look at the stock as management doubles down on solutions to the industry’s biggest problems.

For more information, visit the company’s website.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading